在大健康领域，公司依托中医药产业优势，布局"药食同源"产品，构建"治疗+调理+预防"的全生命周期产品体系。目前，公 司已研发多款保健品和功能性食品，部分产品即将上市。营销方面，公司计划通过线上线下（300959）协同、场景化营销及 电商合作提升品牌影响力，探索新的业绩增长空间。 研发与并购双轮驱动，强化长期竞争力 5月以来，盘龙药业（002864）(证券代码：002864)密集接受机构调研，通过业绩说明会、路演活动及现场参观等形式，向 投资者详细介绍了公司战略布局、核心产品竞争力及未来发展规划。从披露的投资者关系记录表中可以看出，盘龙药业正通 过"一体两翼三纵深"战略，持续强化主业优势，同时积极拓展中药配方颗粒、大健康等新兴业务，推动业绩稳健增长。 中药配方颗粒与大健康业务成为新增长点 盘龙药业的主导产品盘龙七片是公司业绩增长的重要引擎。该产品作为全国独家专利中成药和医保甲类产品，已入选七部国 家级临床诊疗指南、三个专家共识及多本权威教材，并被推荐为临床用药。2024年上半年，盘龙七片在我国城市及县级公立 医院骨骼肌肉系统风湿性疾病领域中成药市场中的份额达8.05%，排名第一。此外，公司围绕风湿骨伤领域构建了 ...

Core Viewpoint - The company, Panlong Pharmaceutical, has transformed from a near-bankrupt small factory into a nearly 10 billion yuan traditional Chinese medicine listed enterprise over 27 years, focusing on high-quality development and a comprehensive health strategy [1] Group 1: Corporate Governance and Development Strategy - The company integrates party building into its governance structure, with all board members being party committee members, ensuring that the party organization has real power in strategic decision-making [2] - The unique "12345" party building model has led to significant operational improvements, including a 40% efficiency increase in tablet production lines and over 10 million yuan in annual cost savings [2] - The company has achieved a 45.28% growth in main business revenue and a 47.89% increase in net profit over the past five years, with R&D investment consistently exceeding 6% [2] Group 2: Product and Market Development - In 2024, the company's self-produced traditional Chinese medicine generated revenue of 645 million yuan, a year-on-year increase of 10.20%, with its revenue share rising from 59.67% to 66.22% [4] - The company aims to become a leading player in the Chinese herbal formula granules market, targeting over 400 products for production and sales [4] Group 3: Social Responsibility and Community Engagement - The company has implemented a "Five Guarantees Poverty Alleviation Model," resulting in an average annual income increase of 24,000 yuan for 7,520 households [5][6] - Panlong Pharmaceutical has established a 100 million yuan charitable fund and has been recognized as a national green factory, contributing to local economic development and social welfare [6] Group 4: Future Outlook - The company plans to deepen its "one body, two wings, three depths" development strategy by focusing on orthopedic chronic diseases and enhancing its product matrix across various therapeutic areas by 2025 [7]

证券代码： 002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司投资者关系活动记录表 编号：2025-005 | 投资者关系活动 □ | 特定对象调研 □ 分析师会议 | | --- | --- | | 类别 □ | 媒体采访 业绩说明会 □ | | □ | 新闻发布会 ☑ 路演活动 | | □ | 现场参观 | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 万家基金 杨梦朝 | | 人员姓名 | 招商基金 夏帅 | | | 鹏扬基金 曹敏 | | | 长城基金 龙宇飞 | | | 长城证券 蔡航 | | | 长城证券 刘鹏 | | | 标普全球市场财智 孔冰逸 | | | 荣疆投资 彭卫 | | | 银河证券 宋丽莹 | | | 东方财富证券 何玮 | | | 深圳市同城投资管理有限公司 裘伯元 | | 时间 2025 | 年 月 日 6 23 日-25 | | 地点 | 陕西盘龙药业集团股份有限公司、上海浦东新区、湖南长沙市 | | 上市公司接待人 | 董事会秘书吴杰，证券事务代表赵晓妮，投资者关系管理专员梁 | | 员姓名 馨方 | | | 投资者关系活动 主要内容 ...

盘龙药业（002864.SZ） 公司深度报告 公司深度报告 | 盘龙药业（002864.SZ） 2025 年 06 月 11 日 主导产品盘龙七片竞争优势突出。盘龙七片是周恩来总理曾两次亲切接 见的我国著名骨伤科专家王家成老先生所献祖传秘方，经科学研制而成。 为全国独家专利、医保甲类品种，并被评为陕西省名牌产品和"秦药"优 势中成药。2024 年 H1 在我国城市及县级公立医院骨骼肌肉系统风湿性 疾病领域中成药市场中，公司主导产品盘龙七片市场份额排名第一，市场 份额为 8.05%，市占率不断提升。销售额从 2015 年的 1.55 亿元增长至 2023 的 4.1 亿元，年复合增长率达 12.93%，2024 年 H1 盘龙七片销售额 达 2.23 亿元。该产品已构建起差异化的市场竞争壁垒，在风湿骨病治疗 领域形成独特的临床价值优势。 2025 年 06 月 11 日 中药Ⅲ行业 配方颗粒推动第二增长曲线。中药饮片业务中配方颗粒为公司的重点发 展方向。报告期内，公司中药配方颗粒业务已完成 211 个品种的备案，并 计划通过定增募投项目扩大生产规模，目标是将备案品种增至 400 个以 上。公司致力于成为陕西省第 ...

证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司投资者关系活动记录表 编号：2025-003 | 投资者 | □特定对象调研□分析师会议 | | --- | --- | | 关系活 | □媒体采访√业绩说明会 | | 动类别 | □新闻发布会□路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 参与单 | 投资者网上提问 | | 位名称 | | | 及人员 | | | 姓名 | | | 时间 | 年 月 日(周五)下午 2025 5 23 15:00-17:00 | | 地点 | 公司通过同花顺路演平台 | | | （https://board.10jqka.com.cn/rs/pc/detail?roadshowId=1010568） | | | 采用网络远程的方式召开业绩说明会 | | 上市公 | | | 司接待 | 董事长谢晓林、独立董事牛晓峰、董事会秘书吴杰、副总裁张德柱、财务 | | 人员姓 | 总监祝凤鸣 | | 名 | | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | 投资 ...

继盘龙药业（002864）（002864.SZ）4月下旬披露2024年年报后，5月12日及20日，公司先后开展两轮 年度业绩说明会。在中药行业整体表现不佳的背景下，盘龙药业以其2024年全年及2025年一季度相对稳 定的业绩，以及上市8年来保持稳步增长的利润表现，吸引了众多投资者关注。值得关注的是，在两轮 说明会交流过程中，公司在研发创新层面的投入与进展，成为投资者最为关注的话题。 5月16日，公司也召开了年度股东会，由董事长谢晓林主持，全体董事、监事和董秘出席，高管列席本 次会议，线上线下（300959）表决通过了2024年年报等一系列文件，为公司后续稳步发展提供支撑。 据了解，围绕盘龙七片二次开发，公司联合西安交通大学、陕西科技大学、中国药科大学等，近两年完 成盘龙七片治疗骨折的真实世界研究及药物经济学、质量标准提升、药效机制等一系列研究，累计发表 高水平学术论文13篇，包括SCI文章4篇，以产品临床价值筑牢市场地位。 优势中成药品种作用机制研究、工艺优化、质量标准升级以及新剂型、新适应症的开发，正是公司四大 研发方向之一。更进一步，公司现已形成盘龙七片、盘龙七药酒、骨松宝片、痛风舒片、抗骨增生片、 腰痛 ...

编号：2025-002 | 投资者关系活动 | □特定对象调研□分析师会议 | | --- | --- | | 类别 | □媒体采访√业绩说明会 | | | □新闻发布会□路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日(周二)下午 2025 5 20 15:00-17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 独立董事焦磊鹏、董事会秘书吴杰、财务总监祝凤鸣、证券事务 | | 员姓名 | 代表赵晓妮、IR 梁馨方、财务经理程茜 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | Q1：请问国家医药集采对盘龙未来业绩影响大吗，有什么具 | | | 体举措来应对？另外，盘龙业绩连续八年增长，但股价长期低于 | | | 23 年增发价，影响广大投资者利益，公司有什么市值管理措施？ | | | A ...

Core Viewpoint - The company, Panlong Pharmaceutical, has demonstrated steady growth in its operations and profitability in 2024, with significant advancements in its product offerings and market position in the field of rheumatology and bone injuries [1][4][12]. Group 1: Company Performance - In 2024, Panlong Pharmaceutical achieved a revenue of 974 million yuan, remaining stable compared to the previous year, with a 10.20% year-on-year growth in self-produced traditional Chinese medicine (TCM) business [4][5]. - The company reported a net profit of 120 million yuan in 2024, marking an 8.91% increase year-on-year, continuing its profit growth for eight consecutive years since its listing [5][8]. - The gross profit margin for the company improved to 60.82%, an increase of nearly 2.9 percentage points from the previous year [5]. Group 2: Product Development and Market Position - The flagship product, Panlong Seven, holds the largest market share in the TCM market for musculoskeletal and rheumatic diseases, with a market share of 8.05% [3][4]. - The company has expanded its product matrix, achieving a three-digit growth rate in its subsidiary, Panlong Plant Medicine, and has registered 211 varieties of formula granules, marking a significant breakthrough [1][4]. Group 3: Innovation and R&D - In 2024, the company increased its R&D investment to 37.54 million yuan, representing an 85.31% increase from 2023, which is 5.05% of its self-produced TCM revenue [9][10]. - The company has established multiple research platforms and is actively developing innovative TCM products, with a focus on high-quality manufacturing and digital transformation [9][10]. Group 4: Marketing and Distribution - Panlong Pharmaceutical has built a comprehensive marketing network across 30 provinces in China, collaborating with over 630 pharmaceutical companies to distribute its products to more than 4,800 hospitals and 7,000 pharmacies [11]. - The company is also embracing e-commerce by launching official flagship stores on platforms like Tmall and JD, enhancing its market reach [11]. Group 5: Industry Outlook - The TCM industry is experiencing a golden period driven by policy, demand, and technology, with Panlong Pharmaceutical positioned to benefit from these trends [12][13]. - The company's strategic vision focuses on becoming a leader in rheumatology and pain management, aiming for high-quality development and increased operational efficiency [13].

证券代码： 002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司投资者关系活动记录表 编号：2025-001 | 投资者关系活动 | □特定对象调研 分析师会议 □ | | --- | --- | | 类别 | 业绩说明会 □ 媒体采访 √ | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日 (周一) 下午 2025 5 12 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 董事长谢晓林、副总裁张德柱、董事会秘书吴杰、财务总监祝凤 | | 员姓名 | 鸣、独立董事任海云、独立董事牛晓峰、保荐代表人杨圣志 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： Q1:2024 年医药商业配送业务收入同比下降 36.72%，"一体 | | | 两翼"战略是否失衡？ ...

Core Viewpoint - The performance meeting of Panlong Pharmaceutical for the year 2024 highlighted the company's steady growth, innovative strategies, and commitment to social responsibility, with a focus on traditional Chinese medicine and modern pharmaceutical development [1][4][9]. Financial Performance - In 2024, Panlong Pharmaceutical achieved a revenue of 974 million yuan and a net profit attributable to shareholders of 120 million yuan, representing a year-on-year growth of 8.91% [7]. - The sales revenue of the leading products experienced double-digit growth, while the plant medicine sector saw a three-digit increase [7]. Product Development and Innovation - The company has made significant advancements in research and development, particularly in new traditional Chinese medicine, chemical drugs, and medical institution formulations [7]. - The self-developed innovative traditional Chinese medicine PLZY-001 is accelerating clinical exploration, and several chemical generic drugs have successfully completed pilot tests [7]. - The establishment of the Panlong Xinyuan (Guangdong) New Drug Research and Transformation Base in the Guangdong-Hong Kong-Macao Greater Bay Area aims to enhance innovation capabilities [7]. Strategic Vision and Future Plans - The company plans to increase cash dividends to shareholders, proposing a cash dividend of 31.77 million yuan, which accounts for 26.42% of net profit [9]. - The strategic vision includes becoming a leader in the field of wind and bone injury medications and a specialist in chronic pain management, with a focus on a comprehensive development strategy [9]. - The company aims to enhance its governance and operational efficiency through a specialized and compliant marketing organization and a robust research and development system [9][11].